CRDF - Cardiff Oncology, Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

40.58M

Cash

67.19M

Avg Qtr Burn

-7.492M

Short % of Float

12.38%

Insider Ownership

7.55%

Institutional Own.

23.92%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Onvansertib + nanoliposomal irinotecan (Onyvide®) (PLK1) Details Cancer, Pancreatic cancer, Solid tumor/s	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onvansertib (monotherapy) Details Cancer, Small cell lung cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onvansertib + SOC (FOLFIRI + bevacizumab or FOLFOX + bevacizumab) Details Cancer, Metastatic colorectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onvansertib + decitabine (inhibitor of Polo-like Kinase 1) Details Cancer, Acute myeloid leukemia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onvansertib + Zytiga (abiraterone) Details Prostate cancer, Cancer, Castration-resistant prostate cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onvansertib + Paclitaxel Details Cancer, Triple-negative breast cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onvansertib + Second-Line Standard-of-Care (PLK1) Details Colorectal cancer , Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.